BIA 10-2474首次人体研究中的统计学问题：忽视了方案与实际情况的比较。
Statistical issues in first-in-human studies on BIA 10-2474: Neglected comparison of protocol against practice.
作者信息
Bird Sheila M, Bailey Rosemary A, Grieve Andrew P, Senn Stephen
机构信息
MRC Biostatistics Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK.
School of Mathematics and Statistics, University of St Andrews, St Andrews, UK.
出版信息
Pharm Stat. 2017 Mar;16(2):100-106. doi: 10.1002/pst.1801. Epub 2017 Feb 16.
Abstract
By setting the regulatory-approved protocol for a suite of first-in-human studies on BIA 10-2474 against the subsequent French investigations, we highlight 6 key design and statistical issues, which reinforce recommendations by a Royal Statistical Society Working Party, which were made in the aftermath of cytokine release storm in 6 healthy volunteers in the United Kingdom in 2006. The 6 issues are dose determination, availability of pharmacokinetic results, dosing interval, stopping rules, appraisal by safety committee, and clear algorithm required if combining approvals for single and multiple ascending dose studies.
摘要
通过将针对BIA 10-2474的一系列首次人体研究的监管批准方案与随后的法国调查进行对比，我们突出了6个关键的设计和统计问题，这些问题强化了皇家统计学会工作小组的建议，该建议是在2006年英国6名健康志愿者发生细胞因子释放风暴之后提出的。这6个问题是剂量确定、药代动力学结果的可用性、给药间隔、停止规则、安全委员会的评估，以及如果合并单次和多次递增剂量研究的批准所需的明确算法。
相似文献
1
Statistical issues in first-in-human studies on BIA 10-2474: Neglected comparison of protocol against practice.BIA 10-2474首次人体研究中的统计学问题：忽视了方案与实际情况的比较。
Pharm Stat. 2017 Mar;16(2):100-106. doi: 10.1002/pst.1801. Epub 2017 Feb 16.
2
Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers.FAAH 抑制剂 BIA 10-2474 的安全性、耐受性和药代动力学：在健康志愿者中进行的一项双盲、随机、安慰剂对照研究。
Clin Pharmacol Ther. 2022 Feb;111(2):391-403. doi: 10.1002/cpt.2290. Epub 2021 Jun 24.
3
Lessons from the fatal French study BIA-10-2474.来自法国致命研究BIA-10-2474的教训。
BMJ. 2016 May 18;353:i2727. doi: 10.1136/bmj.i2727.
4
A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.一项针对HMN-214（一种具有与polo样激酶-1相互作用特性的新型口服芪衍生物）在晚期实体瘤患者中的I期药代动力学研究。
Clin Cancer Res. 2006 Sep 1;12(17):5182-9. doi: 10.1158/1078-0432.CCR-06-0214.
5
Implications of the BIA-102474-101 study for review of first-into-human clinical trials.BIA - 102474 - 101研究对首次人体临床试验审查的启示
Br J Clin Pharmacol. 2016 Apr;81(4):582-6. doi: 10.1111/bcp.12920.
6
TGN-1412 and BIA-2474 Trials with Tragic End: Lessons Learnt To Make Clinical Trials Safer.TGN-1412和BIA-2474试验的悲剧结局：为使临床试验更安全而吸取的教训
Rev Recent Clin Trials. 2018;13(4):252-256. doi: 10.2174/1574887113666180521093529.
7
8
Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.脂肪酸酰胺水解酶抑制剂引发的急性神经障碍
N Engl J Med. 2016 Nov 3;375(18):1717-1725. doi: 10.1056/NEJMoa1604221.
9
The Bial 10-2474 Phase 1 Study-A Drug Development Perspective and Recommendations for Future First-in-Human Trials.比亚尔10-2474一期研究——药物开发视角及对未来首次人体试验的建议
J Clin Pharmacol. 2017 Jun;57(6):690-703. doi: 10.1002/jcph.889. Epub 2017 Apr 7.
10
Open letter on access to the BIA 10-2474 clinical trial data.关于获取BIA 10-2474临床试验数据的公开信。
Lancet. 2017 Jan 14;389(10065):156. doi: 10.1016/S0140-6736(16)32515-6. Epub 2016 Dec 10.
引用本文的文献
1
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols.SPIRIT-DEFINE解释与阐述：提高早期剂量探索性临床试验方案质量与影响力的建议
EClinicalMedicine. 2025 Jan 10;79:102988. doi: 10.1016/j.eclinm.2024.102988. eCollection 2025 Jan.
2
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials.CONSORT-DEFINE解释与阐述：提高早期剂量探索性临床试验报告质量和影响力的建议
EClinicalMedicine. 2025 Jan 10;79:102987. doi: 10.1016/j.eclinm.2024.102987. eCollection 2025 Jan.
3
Pharmacohistory of Cannabis Use-A New Possibility in Future Drug Development for Gastrointestinal Diseases.大麻使用的药物史——未来胃肠道疾病药物开发的新可能性。
Int J Mol Sci. 2023 Sep 28;24(19):14677. doi: 10.3390/ijms241914677.
4
Engineering choroid plexus-on-a-chip with oscillatory flow for modeling brain metastasis.构建具有振荡流的类脉络丛芯片用于模拟脑转移。
Mater Today Bio. 2023 Aug 19;22:100773. doi: 10.1016/j.mtbio.2023.100773. eCollection 2023 Oct.
5
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study.共识驱动的 SPIRIT 和 CONSORT 扩展在早期阶段剂量发现试验中的发展：DEFINE 研究。
BMC Med. 2023 Jul 5;21(1):246. doi: 10.1186/s12916-023-02937-0.
6
Human CNS barrier-forming organoids with cerebrospinal fluid production.具有脑脊液产生功能的人中枢神经系统类器官。
Science. 2020 Jul 10;369(6500). doi: 10.1126/science.aaz5626. Epub 2020 Jun 11.
7
A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data.一种使用截尾毒性发生时间数据的组合疗法I期试验的无贝叶斯模型方法。
J R Stat Soc Ser C Appl Stat. 2019 Feb;68(2):309-329. doi: 10.1111/rssc.12323. Epub 2018 Nov 22.
8
How to design a dose-finding study using the continual reassessment method.如何使用连续评估法设计剂量探索研究。
BMC Med Res Methodol. 2019 Jan 18;19(1):18. doi: 10.1186/s12874-018-0638-z.
9
Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.从 IDeAl 中吸取的教训——IDeal-net 关于小人群临床试验设计和分析的 33 条建议。
Orphanet J Rare Dis. 2018 May 11;13(1):77. doi: 10.1186/s13023-018-0820-8.
10
Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.神经性和炎性疼痛的转化药物研究中的挑战：新范式的先决条件
Eur J Clin Pharmacol. 2017 Oct;73(10):1219-1236. doi: 10.1007/s00228-017-2301-8. Epub 2017 Sep 11.
本文引用的文献
1
Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.脂肪酸酰胺水解酶抑制剂引发的急性神经障碍
N Engl J Med. 2016 Nov 3;375(18):1717-1725. doi: 10.1056/NEJMoa1604221.
2
Implications of the BIA-102474-101 study for review of first-into-human clinical trials.BIA - 102474 - 101研究对首次人体临床试验审查的启示
Br J Clin Pharmacol. 2016 Apr;81(4):582-6. doi: 10.1111/bcp.12920.
3
France releases interim report on drug trial disaster.法国公布药物试验灾难的中期报告。
Lancet. 2016 Feb 13;387(10019):634-635. doi: 10.1016/S0140-6736(16)00318-4.
4
French drug trial had three major failings, says initial report.初步报告称，法国药物试验存在三大缺陷。
BMJ. 2016 Feb 8;352:i784. doi: 10.1136/bmj.i784.
5
Details of French trial must be released urgently, say UK experts.英国专家表示，法国试验的细节必须紧急公布。
BMJ. 2016 Jan 18;352:i319. doi: 10.1136/bmj.i319.
6
Critical aspects of the Bayesian approach to phase I cancer trials.贝叶斯方法在I期癌症试验中的关键方面。
Stat Med. 2008 Jun 15;27(13):2420-39. doi: 10.1002/sim.3230.
7
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.抗CD28单克隆抗体TGN1412 1期试验中的细胞因子风暴
N Engl J Med. 2006 Sep 7;355(10):1018-28. doi: 10.1056/NEJMoa063842. Epub 2006 Aug 14.
8
A proposed charter for clinical trial data monitoring committees: helping them to do their job well.一份关于临床试验数据监测委员会的拟议章程：助力其出色履行职责。
Lancet. 2005;365(9460):711-22. doi: 10.1016/S0140-6736(05)17965-3.
9
Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers.用于健康志愿者剂量递增研究的易于实施的贝叶斯方法。
Biostatistics. 2001 Mar;2(1):47-61. doi: 10.1093/biostatistics/2.1.47.
10
Cancer phase I clinical trials: efficient dose escalation with overdose control.癌症I期临床试验：通过过量控制实现有效剂量递增。
Stat Med. 1998 May 30;17(10):1103-20. doi: 10.1002/(sici)1097-0258(19980530)17:10<1103::aid-sim793>3.0.co;2-9.
Zotero 插件